Received: 9 August 2022
Accepted: 26 September 2022
First Online: 26 October 2022
: The study protocol and all amendments were approved by the institutional review board/ethics committee at each site. All patients provided written informed consent prior to study participation.
: Not applicable.
: JEC has received consulting fees from Astellas Pharma, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, and Pfizer; and institutional research funding from Arog, Astellas Pharma, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, and Pfizer. TLL has received institutional research funding from AbbVie, Aptevo, Astellas Pharma, BioPath Holdings, Celgene, Celyad, Genentech/Roche, Gilead Sciences, Incyte, Jazz Pharmaceuticals, Mateon Therapeutics, Ono Pharmaceutical, Pfizer, Prescient Therapeutics, Seattle Genetics, Tolero Pharmaceuticals, and Trovagene. KA is a former employee of Jazz Pharmaceuticals. SF is a current employee of and holds stock or stock options in Jazz Pharmaceuticals. JEL has received consulting fees from Agios, Daiichi Sankyo, Jazz Pharmaceuticals, and Pfizer. TP has received institutional research funding and consulting fees from Jazz Pharmaceuticals.